Files
Download Full Text (432 KB)
Description
Nationwide prevalence of obesity is related to comorbidities including heart disease, type 2 diabetes, and stroke. The United States spends nearly $173 billion annually for the medical cost of obesity, and obese adults have a difference of $1,861 of medical costs than those with healthy weight (CDC, 2022). Overweight individuals experience chronic health issues, resuling in a significant financial burden due to increased costs associated with medical treatment. Ozempic is a newly approved drug accepted by the FDA in 2017 to treat diabetes but is now gradually being implemented as a weight loss medication. It is used in conjunction with exercise and diet in adults with type 2 diabetes mellitus to improve glycemic control; however, continuous nutrition treatment is necessary in order to prevent rebound weight gain. Obesity is a significant public health challenge in the United States resulting from lack of access to education and networks to health and nutrition. Ethnicity and a community’s socio-economic factors play a role in proper access to education of healthy management of weight loss. Further problems arise when young adults discontinue weight loss medication without the proper support of nutrition education and an exercise regime. In order to sustain clinical weight loss and decrease the susceptibility of comorbid risks, lifestyle interventions are advised (Amaro, 2022). There is limited research on interventions to help with preventing weight gain after discontinuing medication.
Department
Nursing
Publication Date
2024
Sponsorship/Conference/Institution
Scholar & Creative Works Conference, Dominican University of California
City
San Rafael, CA
Keywords
adolescents, school-based interventions, health conditions, diet, weight loss
Disciplines
Education | Food Studies | Nursing | Social and Behavioral Sciences